{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:24:49Z","timestamp":1790663089743,"version":"4.1.0"},"reference-count":71,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2018,2,23]],"date-time":"2018-02-23T00:00:00Z","timestamp":1519344000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0193380","type":"journal-article","created":{"date-parts":[[2018,2,23]],"date-time":"2018-02-23T19:18:07Z","timestamp":1519413487000},"page":"e0193380","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":79,"title":["Preclinical pharmacology of AZD9977: A novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion"],"prefix":"10.1371","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0538-6083","authenticated-orcid":true,"given":"Krister","family":"Bamberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrika","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Edman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"William-Olsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Myhre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Gunnarsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Geschwindner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Aagaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Bj\u00f6rnson Granqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Jaisser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufeng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth L.","family":"Granberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasmus","family":"Jansson-L\u00f6fmark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Hartleib-Geschwindner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2018,2,23]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0083-6729(03)01002-1","article-title":"Aldosterone: its receptor, target genes, and actions","volume":"66","author":"D Pearce","year":"2003","journal-title":"Vitamins and hormones"},{"issue":"2","key":"ref2","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1161\/01.CIR.92.2.175","article-title":"Prerequisite for cardiac aldosterone action. Mineralocorticoid receptor and 11 beta-hydroxysteroid dehydrogenase in the human heart","volume":"92","author":"M Lombes","year":"1995","journal-title":"Circulation"},{"issue":"4","key":"ref3","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1161\/01.HYP.0000154681.38944.9a","article-title":"Involvement of aldosterone and mineralocorticoid receptors in rat mesangial cell proliferation and deformability","volume":"45","author":"A Nishiyama","year":"2005","journal-title":"Hypertension"},{"issue":"2","key":"ref4","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1161\/01.HYP.0000255636.11931.a2","article-title":"Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1","volume":"49","author":"S Shibata","year":"2007","journal-title":"Hypertension"},{"issue":"1","key":"ref5","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/0039-128X(94)00026-9","article-title":"Aldosterone biosynthesis and action in vascular cells","volume":"60","author":"R Takeda","year":"1995","journal-title":"Steroids"},{"issue":"2","key":"ref6","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s00424-008-0616-0","article-title":"<italic>Actions of aldosterone in the cardiovascular system<\/italic>: <italic>the good<\/italic>, <italic>the bad<\/italic>, <italic>and the ugly<\/italic>?","volume":"458","author":"M Gekle","year":"2009","journal-title":"Pflugers Archiv: Eur J Physiol"},{"issue":"2","key":"ref7","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/eurheartj\/ehr176","article-title":"Aldosterone, mortality, and acute ischaemic events in coronary artery disease patients outside the setting of acute myocardial infarction or heart failure","volume":"33","author":"F Ivanes","year":"2012","journal-title":"Eur Heart J"},{"issue":"8","key":"ref8","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/j.bbadis.2016.10.025","article-title":"Role of mineralocorticoid receptor activation in cardiac diastolic dysfunction","volume":"1863","author":"G Jia","year":"2017","journal-title":"Biochim Biophys Acta\u2014Molecular Basis of Disease"},{"issue":"10","key":"ref9","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"B Pitt","year":"1999","journal-title":"N Engl J Med"},{"issue":"1","key":"ref10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"F Zannad","year":"2011","journal-title":"N Engl J Med"},{"issue":"1","key":"ref11","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/HJH.0b013e3283599b6a","article-title":"Spironolactone, eplerenone and the new aldosterone blockers in endocrine and primary hypertension","volume":"31","author":"G Colussi","year":"2013","journal-title":"Journal Hypertens"},{"issue":"10","key":"ref12","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/ki.2011.48","article-title":"Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease","volume":"79","author":"JP Bertocchio","year":"2011","journal-title":"Kidney Int"},{"issue":"2","key":"ref13","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.mce.2011.06.014","article-title":"Mineralocorticoid receptors in vascular function and disease","volume":"350","author":"A McCurley","year":"2012","journal-title":"Mol Cell Endocrinol"},{"issue":"2","key":"ref14","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000345243","article-title":"Vascular actions of aldosterone","volume":"50","author":"M Briet","year":"2013","journal-title":"J Vasc Res"},{"issue":"1","key":"ref15","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1161\/01.HYP.0000171479.36880.17","article-title":"Participation of prostacyclin in endothelial dysfunction induced by aldosterone in normotensive and hypertensive rats","volume":"46","author":"J Blanco-Rivero","year":"2005","journal-title":"Hypertension"},{"issue":"23","key":"ref16","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1161\/01.CIR.0000129307.26791.8E","article-title":"Impaired endothelium-dependent flow-mediated vasodilation in hypertensive subjects with hyperaldosteronism","volume":"109","author":"MK Nishizaka","year":"2004","journal-title":"Circulation"},{"issue":"4","key":"ref17","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s11906-010-0116-4","article-title":"Aldosterone in the pathogenesis of chronic kidney disease and proteinuria","volume":"12","author":"Y Lu","year":"2010","journal-title":"Curr Hypertens Rep"},{"issue":"12","key":"ref18","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1038\/sj.ki.5001854","article-title":"Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease","volume":"70","author":"S Bianchi","year":"2006","journal-title":"Kidney Int"},{"issue":"1","key":"ref19","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1053\/j.ajkd.2005.03.007","article-title":"Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study","volume":"46","author":"S Bianchi","year":"2005","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"ref20","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.jacc.2013.09.056","article-title":"Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients","volume":"63","author":"Y Matsumoto","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"ref21","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1161\/01.HYP.0000067463.13172.EA","article-title":"Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension","volume":"41","author":"WB White","year":"2003","journal-title":"Hypertension"},{"issue":"6","key":"ref22","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1056\/NEJMoa040135","article-title":"Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study","volume":"351","author":"DN Juurlink","year":"2004","journal-title":"New Eng J Med"},{"issue":"3","key":"ref23","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.semnephrol.2014.04.008","article-title":"Prediction and management of hyperkalemia across the spectrum of chronic kidney disease","volume":"34","author":"I Lazich","year":"2014","journal-title":"Sem Nephrol"},{"issue":"1","key":"ref24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/mol.112.079285","article-title":"Small molecule modulation of nuclear receptor conformational dynamics: implications for function and drug discovery","volume":"83","author":"DJ Kojetin","year":"2013","journal-title":"Mol Pharmacol"},{"issue":"6652","key":"ref25","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/39645","article-title":"Molecular basis of agonism and antagonism in the oestrogen receptor","volume":"389","author":"AM Brzozowski","year":"1997","journal-title":"Nature"},{"issue":"5564","key":"ref26","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1126\/science.1068537","article-title":"Molecular determinants for the tissue specificity of SERMs","volume":"295","author":"Y Shang","year":"2002","journal-title":"Science"},{"issue":"6","key":"ref27","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1210\/me.2005-0309","article-title":"Linking ligand-induced alterations in androgen receptor structure to differential gene expression: a first step in the rational design of selective androgen receptor modulators","volume":"20","author":"D Kazmin","year":"2006","journal-title":"Mol Endocrinol"},{"issue":"12","key":"ref28","doi-asserted-by":"crossref","first-page":"7940","DOI":"10.1073\/pnas.122225699","article-title":"Coactivator\/corepressor ratios modulate PR-mediated transcription by the selective receptor modulator RU486","volume":"99","author":"Z Liu","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1\u20132","key":"ref29","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.mce.2007.05.019","article-title":"Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists","volume":"275","author":"C Stahn","year":"2007","journal-title":"Mol Cell Endocrinol"},{"issue":"2","key":"ref30","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1210\/mend.15.2.0596","article-title":"New antiprogestins with partial agonist activity: potential selective progesterone receptor modulators (SPRMs) and probes for receptor- and coregulator-induced changes in progesterone receptor induction properties","volume":"15","author":"G Giannoukos","year":"2001","journal-title":"Mol Endocrinol"},{"issue":"6","key":"ref31","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1210\/me.2004-0537","article-title":"The ligand-dependent interaction of mineralocorticoid receptor with coactivator and corepressor peptides suggests multiple activation mechanisms","volume":"19","author":"ML Hultman","year":"2005","journal-title":"Mol Endocrinol"},{"issue":"3","key":"ref32","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.molcel.2005.06.026","article-title":"Structural and biochemical mechanisms for the specificity of hormone binding and coactivator assembly by mineralocorticoid receptor","volume":"19","author":"Y Li","year":"2005","journal-title":"Mol Cell"},{"issue":"1","key":"ref33","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s10741-005-2344-2","article-title":"Mineralocorticoid receptors: distribution and activation","volume":"10","author":"JW Funder","year":"2005","journal-title":"Heart Fail Rev"},{"issue":"9","key":"ref34","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1042\/CS20080247","article-title":"Mediators of mineralocorticoid receptor-induced profibrotic inflammatory responses in the heart","volume":"116","author":"P Wilson","year":"2009","journal-title":"Clin Sci"},{"issue":"4","key":"ref35","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1161\/HYPERTENSIONAHA.108.114223","article-title":"Corticosteroids and redox potential modulate spontaneous contractions in isolated rat ventricular cardiomyocytes","volume":"52","author":"MF Rossier","year":"2008","journal-title":"Hypertension"},{"issue":"10","key":"ref36","doi-asserted-by":"crossref","first-page":"4145","DOI":"10.1210\/endo.137.10.8828470","article-title":"High glucose stimulates aldosterone-induced hypertrophy via type I mineralocorticoid receptors in neonatal rat cardiomyocytes","volume":"137","author":"A Sato","year":"1996","journal-title":"Endocrinology"},{"issue":"12","key":"ref37","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1016\/j.str.2015.09.012","article-title":"Ligand Binding Mechanism in Steroid Receptors: From Conserved Plasticity to Differential Evolutionary Constraints","volume":"23","author":"K Edman","year":"2015","journal-title":"Structure"},{"issue":"2","key":"ref38","first-page":"125","article-title":"Software XDS for image rotation, recognition and crystal symmetry assignment","volume":"66","author":"W Kabsch","year":"2010","journal-title":"Acta Crystallogr D"},{"issue":"5","key":"ref39","first-page":"760","article-title":"<italic>The CCP4 suite<\/italic>: <italic>programs for protein crystallography<\/italic>","volume":"D50","author":"S Bailey","year":"1994","journal-title":"Acta Crystallogr D"},{"key":"ref40","article-title":"<italic>BUSTER<\/italic>","author":"G Bricogne","year":"2009"},{"issue":"4","key":"ref41","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.str.2016.02.017","article-title":"Outcome of the First wwPDB\/CCDC\/D3R Ligand Validation Workshop","volume":"24","author":"PD Adams","year":"2016","journal-title":"Structure"},{"key":"ref42","unstructured":"Schrodinger. LLC, The JyMOL Molecular Graphics Development Component, Version 1.8. 2015."},{"issue":"2","key":"ref43","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1681\/ASN.2007040510","article-title":"A PAI-1 mutant, PAI-1R, slows progression of diabetic nephropathy","volume":"19","author":"Y Huang","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"e88","DOI":"10.1038\/psp.2013.71","article-title":"Basic concepts in population modeling, simulation, and model-based drug development: part 3-introduction to pharmacodynamic modeling methods","volume":"3","author":"RN Upton","year":"2014","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"14","key":"ref45","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1111\/bph.12856","article-title":"Experimental design and analysis and their reporting: new guidance for publication in BJP","volume":"172","author":"MJ Curtis","year":"2015","journal-title":"Br J Pharmacol"},{"issue":"35","key":"ref46","doi-asserted-by":"crossref","first-page":"31283","DOI":"10.1074\/jbc.M504098200","article-title":"A ligand-mediated hydrogen bond network required for the activation of the mineralocorticoid receptor","volume":"280","author":"RK Bledsoe","year":"2005","journal-title":"J Biol Chem"},{"issue":"6","key":"ref47","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/nsmb939","article-title":"Crystal structure of a mutant mineralocorticoid receptor responsible for hypertension","volume":"12","author":"J Fagart","year":"2005","journal-title":"Nature Struct Biol"},{"issue":"3","key":"ref48","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1124\/mol.107.036459","article-title":"Structural basis of spirolactone recognition by the mineralocorticoid receptor","volume":"72","author":"J Huyet","year":"2007","journal-title":"Mol Pharmacol"},{"issue":"8","key":"ref49","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1210\/me.2004-0203","article-title":"Glucocorticoid receptor point mutation V571M facilitates coactivator and ligand binding by structural rearrangement and stabilization","volume":"19","author":"P Carlsson","year":"2005","journal-title":"Mol Endocrinol"},{"issue":"3","key":"ref50","first-page":"1339","article-title":"An additive effect of eplerenone to ACE inhibitor on slowing the progression of diabetic nephropathy in the db\/db mice","volume":"8","author":"G Zhou","year":"2016","journal-title":"Am J Transl Res"},{"issue":"2","key":"ref51","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.mce.2011.06.025","article-title":"<italic>Molecular pharmacology of the mineralocorticoid receptor<\/italic>: <italic>prospects for novel therapeutics<\/italic>","volume":"350","author":"P Kolkhof","year":"2012","journal-title":"Mol Cell Endocrinol"},{"issue":"1","key":"ref52","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/FJC.0000000000000329","article-title":"Third-generation Mineralocorticoid Receptor Antagonists: Why Do We Need a Fourth?","volume":"67","author":"EP Gomez-Sanchez","year":"2016","journal-title":"J Cardiovasc Pharmacol"},{"issue":"1","key":"ref53","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","article-title":"Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury","volume":"64","author":"P Kolkhof","year":"2014","journal-title":"J Cardiovasc Pharmacol"},{"issue":"31","key":"ref54","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94\u20138862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial","volume":"34","author":"B Pitt","year":"2013","journal-title":"Eur Heart J"},{"issue":"8","key":"ref55","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1517\/13543784.2015.1059819","article-title":"Finerenone: third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease","volume":"24","author":"LC Liu","year":"2015","journal-title":"Expert Opin Investig Drugs"},{"issue":"10","key":"ref56","doi-asserted-by":"crossref","first-page":"4273","DOI":"10.1021\/jm500206r","article-title":"Identification of (R)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-me thoxynicotinic acid, a highly potent and selective nonsteroidal mineralocorticoid receptor antagonist","volume":"57","author":"A Casimiro-Garcia","year":"2014","journal-title":"J Med Chem"},{"issue":"3","key":"ref57","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1254\/jphs.10285FP","article-title":"SM-368229, a novel selective and potent non-steroidal mineralocorticoid receptor antagonist with strong urinary Na+ excretion activity","volume":"115","author":"T Nariai","year":"2011","journal-title":"J Pharmacol Sci"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ejphar.2015.11.028","article-title":"CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, prevents hypertension and cardiorenal injury in Dahl salt-sensitive hypertensive rats","volume":"769","author":"K Arai","year":"2015","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"ref59","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0022-3565(25)25602-6","article-title":"Pharmacology of a new steroid that blocks salt activity of aldosterone and desoxycorticosterone","volume":"126","author":"CM Kagawa","year":"1959","journal-title":"J Pharmacol Exp Ther"},{"issue":"8","key":"ref60","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1002\/cmdc.201200081","article-title":"Discovery of BAY 94\u20138862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases","volume":"7","author":"L Barfacker","year":"2012","journal-title":"Chem Med Chem"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/1479-5876-9-180","article-title":"The use of plasma aldosterone and urinary sodium to potassium ratio as translatable quantitative biomarkers of mineralocorticoid receptor antagonism","volume":"9","author":"RJ Eudy","year":"2011","journal-title":"J Transl Med"},{"key":"ref62","first-page":"284","article-title":"<italic>Vander&apos;s Renal Physiology 8th edition<\/italic>","author":"Dc PVC Eaton","year":"2013"},{"issue":"6","key":"ref63","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMra035279","article-title":"Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system","volume":"351","author":"BF Palmer","year":"2004","journal-title":"New Engl J Med"},{"issue":"5","key":"ref64","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1172\/JCI106577","article-title":"On the adaptation in potassium excretion associated with nephron reduction in the dog","volume":"50","author":"RG Schultze","year":"1971","journal-title":"J Clin Invest"},{"issue":"2","key":"ref65","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/0016-5085(94)90184-8","article-title":"Pathophysiology of potassium absorption and secretion by the human intestine","volume":"107","author":"R Agarwal","year":"1994","journal-title":"Gastroenterology"},{"issue":"5","key":"ref66","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1159\/000168868","article-title":"Extrarenal potassium adaptation: review of a concept","volume":"15","author":"A Spital","year":"1995","journal-title":"Am J Nephrol"},{"issue":"2","key":"ref67","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/ejhf.31","article-title":"Selection of a mineralocorticoid receptor antagonist for patients with hypertension or heart failure","volume":"16","author":"J Iqbal","year":"2014","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"ref68","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1124\/mol.117.108506","article-title":"Structural Analysis of the Glucocorticoid Receptor Ligand-Binding Domain in Complex with Triamcinolone Acetonide and a Fragment of the Atypical Coregulator, Small Heterodimer Partner","volume":"92","author":"ER Weikum","year":"2017","journal-title":"Mol Pharmacol"},{"issue":"2","key":"ref69","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.coph.2006.10.009","article-title":"Estrogens and SERMs in coronary heart disease","volume":"7","author":"V Regitz-Zagrosek","year":"2007","journal-title":"Curr Opin Pharmacol"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1471-2369-14-42","article-title":"The mineralocorticoid receptor antagonist eplerenone reduces renal interstitial fibrosis after long-term cyclosporine treatment in rat: antagonizing cyclosporine nephrotoxicity","volume":"14","author":"FT Nielsen","year":"2013","journal-title":"BMC Nephrol"},{"issue":"1","key":"ref71","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s12882-016-0337-0","article-title":"Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis","volume":"17","author":"G Currie","year":"2016","journal-title":"BMC Nephrol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0193380","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:23:23Z","timestamp":1751415803000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0193380"}},"subtitle":[],"editor":[{"given":"Jaap A.","family":"Joles","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,2,23]]},"references-count":71,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2018,2,23]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0193380","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,23]]}}}